The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Actuarial Analysis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Actuarial Analysis


High impact information on Actuarial Analysis

  • By actuarial analysis, we determined that after six years a mean (+/- SD) of 34 +/- 6 percent of the patients in the digoxin group had undergone valve replacement, as compared with only 15 +/- 3 percent of those in the nifedipine group (P < 0.001) [3].
  • When the treatment groups were compared by actuarial analysis, the allopurinol group was found to have a significantly longer time before recurrence of calculi (P less than 0.02) [4].
  • In actuarial analyses, overall survival was worse in patients with P53 antibody (p < 0.0005); in Cox's multivariate analysis, P53 antibody was an independent prognostic variable [5].
  • Actuarial analysis showed that the cumulative probability of developing MS within 15 years was 45% [6].
  • Thus, actuarial analysis showed that patients with limited-stage SCLC and p53-Ab had a median survival time of 10 months, whereas limited-stage SCLC patients without p53-Ab had a 17-month median survival time (p = 0.014).Therefore, serum assay of p53-Ab could help to identify a population of SCLC patients with an especially poor prognosis [7].

Anatomical context of Actuarial Analysis


Associations of Actuarial Analysis with chemical compounds

  • Among patients with localized cancer actuarial analysis of freedom from PSA elevation during flutamide treatment favored those with a 50% or greater PSA decrease (p = 0.006) but in patients with metastatic cancer the analysis revealed no significant difference [10].
  • Busulfan treated patients who are now deceased, have had a median survival of 35 months (range, 13-108) and actuarial analysis shows the total busulfan treated population to have an expected median survival of 48 months [11].
  • Discriminant actuarial analysis revealed no differences between lithium iodine and lithium cupric sulfide longevity [12].
  • The stone rate improved in all three groups (p < 0.005), but using actuarial analysis in the evaluation of calculi-free patients, indapamide, and indapamide plus allopurinol groups were found to have a significantly more favorable effect than diet and fluid treatment (p < 0.02), without any difference between the two drug groups [13].
  • The usefulness of levamisole in prolonged remission and survival time by the actuarial analysis were studied [14].

Gene context of Actuarial Analysis

  • The presence of IGF1-R was associated with a better prognosis, either on relapse-free survival (actuarial analysis: P = 0.004; Cox analysis: P = 0.005) or overall survival (respectively P = 0.003; P = 0.005) [15].
  • 4. Actuarial analysis and Cox regression failed to document a beneficial effect of HLA-A, B, and DR matching in patients receiving either CsA protocol [16].
  • Actuarial analyses of radiation dose grouped with preRT PSA levels found higher radiation dose to be significant (p < 0.05) [17].
  • Actuarial analysis of in-field disease control showed more aggressive treatment improved control whether analyzed by dose level (greater than or equal to 50 Gy vs less than 50 Gy, or TDF greater than 75 vs less than 75) [18].
  • Kaplan-Meier actuarial analyses revealed that cumulative survival of the Alpha-1 prostheses at 12, 24 and 36 months was 98 +/- 1%, 93 +/- 2% and 85 +/- 7% until device malfunction, and 91 +/- 2% 83 +/- 4% and 75 +/- 7% until surgical intervention (revision or explantation) [19].


  1. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Schwartz, M.M., Lan, S.P., Bonsib, S.M., Gephardt, G.N., Sharma, H.M. Am. J. Kidney Dis. (1989) [Pubmed]
  2. Hydrocephalus and epilepsy: an actuarial analysis. Piatt, J.H., Carlson, C.V. Neurosurgery (1996) [Pubmed]
  3. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. Scognamiglio, R., Rahimtoola, S.H., Fasoli, G., Nistri, S., Dalla Volta, S. N. Engl. J. Med. (1994) [Pubmed]
  4. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. Ettinger, B., Tang, A., Citron, J.T., Livermore, B., Williams, T. N. Engl. J. Med. (1986) [Pubmed]
  5. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Peyrat, J.P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J., Soussi, T. Lancet (1995) [Pubmed]
  6. A long-term prospective study of optic neuritis: evaluation of risk factors. Sandberg-Wollheim, M., Bynke, H., Cronqvist, S., Holtås, S., Platz, P., Ryder, L.P. Ann. Neurol. (1990) [Pubmed]
  7. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. Zalcman, G., Trédaniel, J., Schlichtholz, B., Urban, T., Milleron, B., Lubin, R., Meignin, V., Couderc, L.J., Hirsch, A., Soussi, T. Int. J. Cancer (2000) [Pubmed]
  8. Longitudinal follow-up in 145 patients with medically refractory temporal lobe epilepsy treated surgically between 1984 and 1995. Salanova, V., Markand, O., Worth, R. Epilepsia (1999) [Pubmed]
  9. Effects of rhG-CSF (filgrastim) on the recovery of hematopoiesis after high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children: a report from the Children's Cancer and Leukemia Study Group of Japan. Suzue, T., Takaue, Y., Watanabe, A., Kawano, Y., Watanabe, T., Abe, T., Kuroda, Y., Matsushita, T., Kikuta, A., Iwai, A. Exp. Hematol. (1994) [Pubmed]
  10. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. Fowler, J.E., Pandey, P., Seaver, L.E., Feliz, T.P. J. Urol. (1995) [Pubmed]
  11. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Bolin, R.W., Robinson, W.A., Sutherland, J., Hamman, R.F. Cancer (1982) [Pubmed]
  12. Twelve years of clinical experience with lithium pulse generators. Hauser, R.G., Wimer, E.A., Timmis, G.C., Gordon, S., Staller, B., Klodnycky, M., Eisenhauer, A., Goren, C., Moran, J.F., Davis, A.A. Pacing and clinical electrophysiology : PACE. (1986) [Pubmed]
  13. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. Borghi, L., Meschi, T., Guerra, A., Novarini, A. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  14. Chemoimmunotherapy with levamisole during maintenance therapy in children with acute lymphoblastic leukemia. Bogusławska-Jaworska, J., Raus, Z. Arch. Immunol. Ther. Exp. (Warsz.) (1981) [Pubmed]
  15. Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors. Peyrat, J.P., Bonneterre, J., Vennin, P.H., Jammes, H., Beuscart, R., Hecquet, B., Djiane, J., Lefebvre, J., Demaille, A. J. Steroid Biochem. Mol. Biol. (1990) [Pubmed]
  16. A comparison of two cyclosporine protocols at the University of Minnesota. Fryd, D.S., Canafax, D.M., Matas, A.J., Dunn, D., Payne, W.D., Sutherland, D.E., Najarian, J.S. Clinical transplants. (1988) [Pubmed]
  17. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Valicenti, R.K., Gomella, L.G., Ismail, M., Mulholland, S.G., Petersen, R.O., Corn, B.W. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  18. Radiotherapeutic considerations in the treatment of hemangioblastomas of the central nervous system. Smalley, S.R., Schomberg, P.J., Earle, J.D., Laws, E.R., Scheithauer, B.W., O'Fallon, J.R. Int. J. Radiat. Oncol. Biol. Phys. (1990) [Pubmed]
  19. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. Goldstein, I., Newman, L., Baum, N., Brooks, M., Chaikin, L., Goldberg, K., McBride, A., Krane, R.J. J. Urol. (1997) [Pubmed]
WikiGenes - Universities